Literature DB >> 41609

Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings.

T J Crow, H F Baker, A J Cross, M H Joseph, R Lofthouse, A Longden, F Owen, G J Riley, V Glover, W S Killpack.   

Abstract

Dopamine and its metabolites homovanillic acid and dihydroxyphenylacetic acid, noradrenaline, serotonin and its metabolite 5-hydroxyindoleacetic acid, and tryptophan and its metabolite kynurenine have been assayed in 9 schizophrenic and 10 control brains, together with the monoamine-related enzymes tyrosine hydroxylase monoamine oxidase, dopamine-beta-hydroxylase, and catechol-o-methyl-transferase. In schizophrenic brains dopamine, noradrenaline and serotonin were significantly increased in some areas of corpus striatum, but there were no significant changes in enzyme activity or monoamine metabolite concentrations in any of the brain areas examined. The findings are not consistent with theories that serotonin or noradrenaline stores are grossly depleted or noradrenaline neurones have degenerated, or that monoamine oxidase activity is abnormal, in schizophrenia, and provide no direct support for the hypothesis that dopamine neurones are overactive.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41609     DOI: 10.1192/bjp.134.3.249

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  23 in total

1.  Striatal dopamine and homovanillic acid in Huntington's disease.

Authors:  G P Reynolds; N J Garrett
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 2.  The biology of schizophrenia.

Authors:  T J Crow
Journal:  Experientia       Date:  1982-11-15

Review 3.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

Review 4.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

Authors:  Ikwunga Wonodi; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-02-10       Impact factor: 9.306

5.  Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters.

Authors:  Lesley A McCollum; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

6.  Dopamine metabolism increases in post-mortem schizophrenic basal ganglia.

Authors:  M Toru; T Nishikawa; N Mataga; M Takashima
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

7.  Distribution of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in human brain in relation to age, drug influence, agonal status and circadian variation.

Authors:  G Bucht; R Adolfsson; C G Gottfries; B E Roos; B Winblad
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

8.  Altered interrelationship of dopamine, prolactin, thyrotropin and thyroid hormone in schizophrenic patients.

Authors:  M L Rao; G Gross; G Huber
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

9.  Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia.

Authors:  Igor Elman; David Rott; Alan I Green; Daniel D Langleben; Scott E Lukas; David S Goldstein; Alan Breier
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

10.  Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet.

Authors:  F Owen; H F Baker; R M Ridley; A J Cross; T J Crow
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.